Browse drugs

…% CI 23.7 – 50.3)) SELADELPAR (ARR = 40.9 (95% CI 28.1 – 53.8)) ELAFIBRANOR (ARR = 47.2 (95% CI 36.4 – 57.9)) ARR = 10.2 (-6.9 ; 27,3) p = …

…olone 2 mg/kg for at least 72 hours and underwent liver biopsy. Ursodeoxycholic acid was added in mixed and cholestatic drug-induced liver injury (D…

…stasis, persistent inflammation and, over time, fibrogenesis. 1 Ursodeoxycholic acid (UDCA) remains the first-line therapy and has significantly imp…

…longed. Response to immunosuppression is limited and initiating UDCA can be considered in all patients.…

…ions of the biliary duct ( figure 1). PBC has been treated with ursodeoxycholic acid since 2012.…

…3 F to the tumour bed. After each irradiation, a 250 mg dose of UDCA will be topically administered to the irradiated area. Radiolog…

…Immunosuppression 100 (27%)• Azathioprine (38)• Budesonide (7)• Mercaptopurine (5)• Mycophenolate (40)• Prednisolone (4)• Tacrolimus (6) Prima…

…Seladelpar is a first-in-class delpar (selective PPAR-delta agonist) indic…

…followed by the TB component (3M, −0.11; 1Y, −0.09; 2Y, −0.13). Seladelpar treatment for 3M, 1Y, and 2Y led to predicted changes in TFS wi…

…brates/OCA (total, n = 131; 83%). At month 18, among continuous seladelpar patients, 9/15 (60%) patients with prior fibrate/OCA use achiev…

…py, while 27% were prescribed second-line treatments, including Bezafibrate (31 patients), Obeticholic acid (20 patients), and Elafibranor …

…afibranor initiation. 2 (7.4%) patients continued OCA alongside elafibranor. 19 (70.4%) patients had trialled bezafibrate prior to elafibra…